Increased levels of the cardiovascular disease risk biomarkers GDF15 and myostatin in patients with chronic lymphocytic leukemia. (3rd July 2020)

• Record Type: Journal Article
• Authors: Larsson, Karin; Höglund, Martin; Larsson, Anders; Thulin, Måns; Karlsson, Torbjörn
• Is Part Of: Growth factors. Volume 38:Number 3/4(2020)
• Page Start: 189
• Page End: 196
• Publication Date: 2020-07-03
• Subjects: Chronic lymphocytic leukemia -- inflammation biomarkers -- cardiovascular disease biomarkers -- cytokines; Growth factors -- Periodicals; Physiology -- Periodicals; 611
• DOI: 10.1080/08977194.2021.1932870
• Languages: English
• ISSNs: 0897-7194

Abstract

Abstract: Individuals suffering from cancer, including hematological malignancies, are at increased risk of cardiovascular disease (CVD). Elevated levels of several biomarkers in blood are associated with an increased risk of CVD. The aim of this study was to investigate whether a subset of such CVD risk biomarkers was elevated in patients with untreated chronic lymphocytic leukemia (CLL). Blood plasma and serum from 139 CLL patients and 71 healthy age-matched controls were analyzed for 11 proposed CVD risk biomarkers. The CLL cohort displayed a more heterogeneous pattern of biomarker expression compared to controls. The majority, eight out of 11, analyzed CVD risk biomarkers differed significantly in concentrations between CLL patients and controls. Increased levels of the biomarkers GDF15 and myostatin have not previously been reported in CLL. Further prospective studies are warranted to investigate whether these biomarkers predict future cardiovascular events in patients with CLL.